Search

Xiaolin Hou (Chinese Academy of Sciences) and colleagues published a new paper on advances in engineered phages for disease treatment, showing recent progress in enhancing phage targeting, stability, and synergistic combinations, across ant

🎙️ New Podovirus Podcast Episode Alert! I had such a great time talking to Jesus Fernandez-Rodriguez, PhD, VP of Technology at Eligo Bioscience, about how they're editing live microbes in the mouse gut with engineered phages! 🧬 Highligh

Felix Biotechnology (South San Francisco, California) is hiring a Senior Scientist to work on engineering bacteriophage genomes using novel and cutting edge technologies.

Postdoc: Join the Talbert Research Group at Iowa State University to work on an NIH-funded project focused on bacteriophage engineering for therapeutic applications.

The Sommer Lab at the Novo Nordisk Foundation Centre, Copenhagen is seeking a PhD student to use synthetic biology to develop engineered bacterial therapeutics for the gut microbiome.

Felix Biotechnology is looking for a Scientist to help develop phage therapies targeting multidrug resistant bacterial infections. Responsibilities include engineering phages, isolating and characterizing phage-host interactions and more.

One issue that obstructs phage efficiency in vivo is poor localization of phage to the site of infection. Aurelija Grigonyte (University of Warwick) and colleagues published a new paper in Pharmaceuticals showing how they modified phages to

Peter Voorhees (University of North Carolina-Chapel Hill) and colleagues published a new review in the Journal of Controlled Release on the challenges and opportunities for phage-based in situ microbiome engineering in the gut.

Paul Hyman, Ashland University Are you modifying phages, genetically or chemically, to improve their ability to act as therapeutics? Attaching toxins so the phage capsid provides specificity to target bacteria? Creating phage based vaccines

Kurt Selle (Locus Biosciences) and colleagues, in collaboration with NC State University, have published a new paper in mBio showing that phage-delivered programmable CRISPR therapeutics (recombinant phage expressing host genome-targeting C

Kurt Selle (Locus Biosciences) and colleagues, in collaboration with NC State University, have published a new paper in mBio showing that phage-delivered programmable CRISPR therapeutics (recombinant phage expressing host genome-targeting C